Table 2 Serum-VEGF, serum-bFGF and urinary-bFGF variations, and risk of poor histological response or treatment failure
Risk of poor histological response | Risk of treatment failure | |||||
|---|---|---|---|---|---|---|
Variation between baseline and pre-surgery(T1-T0) | Poor Resp./ Na | Adjusted Odds Ratio (95%CI)b | P value | Event / Nc | Adjusted Hazard Ratio (95%CI)d | P value |
Serum VEGF (N = 165) | 0.26 | 0.67 | ||||
Q1: −1424 to −284 | 12 / 44 | 1 (ref) | 16 / 44 | 1 (ref) | ||
Q2: −279 to --80 | 16 / 43 | 1.55 (0.57–4.2) | 16 / 45 | 1.13 (0.52–2.5) | ||
Q3: −79 to − + 35 | 12 / 39 | 1.39 (0.46–4.2) | 12 / 45 | 0.98 (0.41–2.3) | ||
Q4: − + 39 to +503 | 19 / 39 | 2.63 (0.97–7.1) | 12 / 45 | 0.69 (0.29–1.7) | ||
Serum bFGF (N = 167) | 0.85 | 0.39 | ||||
Q1: −257 to −2.5 | 15 / 44 | 1 (ref) | 14 / 45 | 1 (ref) | ||
Q2: −2.4 to +0.8 | 14 / 44 | 0.66 (0.21–2.0) | 16 / 45 | 0.66 (0.22–2) | ||
Q3: +0.9 to +7.2 | 15 / 40 | 0.89 (0.3–2.7) | 16 / 45 | 0.45 (0.15–1.3) | ||
Q4: +7.8 to +92 | 15 / 39 | 0.92 (0.3–2.9) | 11 / 45 | 0.45 (0.14–1.4) | ||
Urinary bFGF (N = 73) | 0.67 | 0.20 | ||||
Q1: −14.4 to −2.1 | 5 / 18 | 1 (ref) | 11 / 19 | 1(ref) | ||
Q2: −2.1 to +2.4 | 3 / 17 | 0.48 (0.08–3.0) | 2 / 19 | 0.17 (0.03–0.89) | ||
Q3: +2.6 to +12.9 | 5 / 19 | 0.70 (0.13–3.9) | 6 / 20 | 0.54 (0.15–1.9) | ||
Q4: +13.8 to +413 | 7 / 19 | 1.32 (0.30–5.7) | 9 / 19 | 0.51 (0.18–1.5) | ||